ClinicalTrials.govpublic full text
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
cystic fibrosis, creon, pancrelipase, abt-slv-245, exocrine pancreatic insufficiency (epi), interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 906129
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.